CN106187777A - A kind of pharmaceutical composition of cefoperazone - Google Patents
A kind of pharmaceutical composition of cefoperazone Download PDFInfo
- Publication number
- CN106187777A CN106187777A CN201610564494.5A CN201610564494A CN106187777A CN 106187777 A CN106187777 A CN 106187777A CN 201610564494 A CN201610564494 A CN 201610564494A CN 106187777 A CN106187777 A CN 106187777A
- Authority
- CN
- China
- Prior art keywords
- cefoperazone
- pharmaceutical composition
- compound
- elution
- ethanol elution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses pharmaceutical composition and the medical usage thereof of a kind of cefoperazone, containing cefoperazone and the natural product compound (I) of a kind of novel structure in the pharmaceutical composition of the cefoperazone that the present invention provides, when cefoperazone, compound (I) independent role, periodontitis had therapeutical effect；When cefoperazone and compound (I) synergy, therapeutic effect improves further, can be developed into the medicine for the treatment of periodontitis, compared with prior art has prominent substantive distinguishing features and significantly progress.
Description
Technical field
The invention belongs to biomedicine field, relate to the new application of cefoperazone, be specifically related to the medicine group of cefoperazone
Compound and the application in treatment periodontitis thereof.
Background technology
The treatment of the various infection that cefoperazone causes for sensitive zymogenic bacteria, such as respiratory system, urogenital system, gallbladder
Road, gastrointestinal tract, splanchnocoel, the treatment of skin soft-tissue infection, and the brain inner infection causing hemophilus influenza, meningococcus is also
There is preferable curative effect.
Up to now, there is not yet the dependency report of cefoperazone and pharmaceutical composition thereof and treatment periodontitis.
Summary of the invention
It is an object of the invention to provide the pharmaceutical composition of a kind of cefoperazone, containing cephalo piperazine in this pharmaceutical composition
Ketone and a kind of natural product, cefoperazone and this natural product can be with Synergistic treatment periodontitis.
The above-mentioned purpose of the present invention is achieved by techniques below scheme:
A kind of pharmaceutical composition of cefoperazone, the compound (I) that including cefoperazone, there is following structural formula and pharmacy
Upper acceptable carrier, is prepared as the dosage form needed；
As preferably, pharmaceutically acceptable carrier include diluent, excipient, filler, binding agent, wetting agent,
Disintegrating agent, absorption enhancer, surfactant, absorption carrier or lubricant.
As preferably, described dosage form include tablet, capsule, oral liquid, suck agent, granule, electuary, pill, powder,
Unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, spray, drop or patch.
As preferably, described compound (I) be prepared by following steps: Fructus Sinopodophylli is pulverized by (a), with 80～90% second
Alcohol circumfluence distillation, united extraction liquid, it is concentrated into without alcohol taste, successively by petroleum ether, ethyl acetate and water saturated n-butyl alcohol extraction
Take, respectively obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract；B in () step (a), n-butyl alcohol takes thing use
Macroporous resin remove impurity, first with 6 column volumes of 30% ethanol elution, then with 12 column volumes of 85% ethanol elution, collects 85% and washes
De-liquid, concentrating under reduced pressure obtains 85% ethanol elution concentrate；C in () step (b), 85% ethanol elution concentrate purification on normal-phase silica gel is divided
From, obtain 4 components with the methylene chloride-methanol gradient elution that volume ratio is 100:1,50:1,25:1 and 12:1 successively；(d)
In step (c), component 4 separates further by purification on normal-phase silica gel, successively by dichloromethane-first that volume ratio is 20:1,12:1 and 2:1
Alcohol gradient elution obtains 3 components；E reverse phase silica gel that in () step (d), component 2 is bonded by octadecylsilane separates, and uses body
Long-pending percentage concentration is the methanol aqueous solution isocratic elution of 88%, collects 13～16 column volume eluents, eluent concentrating under reduced pressure
Obtain compound (I).
As preferably, described macroporous resin is D101 type macroporous adsorbent resin.
Advantages of the present invention:
Containing cefoperazone and the natural product of a kind of novel structure in the pharmaceutical composition of the cefoperazone that the present invention provides
Thing, when cefoperazone, compound (I) independent role, has therapeutical effect to periodontitis；Cefoperazone and compound (I) associating
During effect, therapeutic effect improves further, can develop into the medicine for the treatment of periodontitis.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula.
Detailed description of the invention
Further illustrate the essentiality content of the present invention below in conjunction with embodiment, but do not limit the present invention with this and protect model
Enclose.Although the present invention being explained in detail with reference to preferred embodiment, it will be understood by those within the art that, can be right
Technical scheme is modified or equivalent, without deviating from the spirit and scope of technical solution of the present invention.
Embodiment 1: compound (I) separates preparation and structural identification
Reagent source: ethanol, petroleum ether, ethyl acetate, n-butyl alcohol, dichloromethane are analytical pure, insults peaking purchased from Shanghai
Learning reagent company limited, methanol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Separation method: Fructus Sinopodophylli (2kg) is pulverized by (a), extracts (15L × 3 time) with 85% alcohol heat reflux, united extraction
Liquid, is concentrated into without alcohol taste (3L), successively with petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol
(3L × 3 time) extract, and respectively obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract；In (b) step (a)
Acetic acid ethyl ester extract D101 type macroporous resin remove impurity, first with 6 column volumes of 30% ethanol elution, then uses 85% ethanol elution
12 column volumes, collect 85% eluent, and concentrating under reduced pressure obtains 85% ethanol elution concentrate；C in () step (b), 85% ethanol is washed
De-concentrate purification on normal-phase silica gel separates, successively with volume ratio be 100:1 (12 column volumes), 50:1 (10 column volumes), 25:1
The methylene chloride-methanol gradient elution of (8 column volumes) and 12:1 (8 column volumes) obtains 4 components；Group in (d) step (c)
Points 4 separate further by purification on normal-phase silica gel, successively with volume ratio be 20:1 (6 column volumes), 12:1 (8 column volumes) and 2:1 (6
Individual column volume) methylene chloride-methanol gradient elution obtain 3 components；E in () step (d), component 2 uses octadecylsilane
The reverse phase silica gel of bonding separates, and with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 88%, collects 13～16 cylinders
Long-pending eluent, eluent is concentrated under reduced pressure to give compound (I) (HPLC normalization purity is more than 98%).
Structural identification: HR-ESIMS shows [M+H]+For m/z 340.2196, can obtain molecular formula in conjunction with nuclear-magnetism feature is
C22H28O2, degree of unsaturation is 9.Hydrogen nuclear magnetic resonance modal data δH(ppm, CDCl3, 500MHz): H-2a (1.36, m), H-2b
(1.46, m), H-3a (1.73, m), H-3b (2.04, m), H-5 (2.46, d, J=10.9Hz), H-6 (5.26, dt, J=10.2,
3.1Hz), H-7 (5.38, br, t, J=6.5Hz), H-9a (2.11, dd, J=13.2,2.7Hz), H-9b (2.22, br, t, J=
12.3Hz), and H-10a (1.37, m), H-10b (1.67, m), H-11 (1.76, s), H-13 (1.91, s), H-14 (1.93, s), H-
15 (1.02, s), H-2 ', 6 ' (7.94, d, J=8.6Hz), H-3 ', 5 ' (7.57, d, J=8.6Hz), H-4 ' (7.64, d, J=
8.6Hz)；Carbon-13 nmr spectra data δC(ppm, CDCl3, 125MHz): 43.2 (C, 1-C), 38.3 (CH2, 2-C), 29.2
(CH2, 3-C), 153.2 (C, 4-C), 53.2 (CH, 5-C), 75.2 (CH, 6-C), 121.1 (CH, 7-C), 136.1 (C, 8-C),
31.1(CH2, 9-C), 41.7 (CH2, 10-C), 25.7 (CH3, 11-C), 114.2 (C, 12-C), 19.4 (CH3, 13-C), 22.1
(CH3, 14-C), 18.4 (CH3, 15-C), 167.6 (C, C=O), 133.5 (C, 1 '-C), 123.3 (CH, 2 ', 6 '-C), 125.1
(CH, 3 ', 5 '-C), 133.3 (CH, 4 '-C).IR spectrum shows that this compound contains ester carbonyl group (1678cm-1).The hydrogen of compound
Spectrum shows that this compound has a mono-substituted phenyl ring proton signal [δH7.94 (2H, d, J=8.6Hz, H-2 ', 6 '), 7.57
(2H, d, J=8.6Hz, H-3 ', 5 ') and 7.64 (1H, d, J=8.6Hz, H-4 ')], an olefinic methine proton signal [δH5.38 (1H, br, t, J=6.5Hz, H-7)], a company oxygen methine proton signal [δH5.26 (1H, dt, J=10.2,
3.1Hz, H-6)], and four methyl proton signal [δH1.76 (3H, s, H-11), 1.91 (3H, s, H-13), 1.93 (3H, s,
H-14), 1.02 (3H, s, H-15)].The carbon spectrum of this compound shows that this compound has 22 carbon signals, including four methyl, and four
Individual methylene, eight methines (six alkene carbon, company's oxygen carbon) and six quaternary carbons (an ester carbonyl group carbon, four alkene
Quaternary carbon).Preliminary HSQC and HMBC spectrum resolves and finds, H-6 '/C-CO, H-6 '/C-2 ', H-4 '/C-2 ', H-5 '/C-3 ' with
And the dependency of H-6 '/C-5 ' can connect a mono-substituted benzoyl signal.Remove 7 carbon of benzoyl, change
Compound there remains 15 carbon signals, can be inferred that this compound is a sesquiterpenoids derivant with this.Consult pertinent literature
Finding, this compound has similar structure with known compound elaeochytrin B.Relatively both nuclear magnetic resonance datas
It is found that the difference of noval chemical compound and elaeochytrin B is position of double bond and the difference of number and benzoyl
The replacement mode of base is different.First, the dependency explanation benzoyl between H-6/C-CO is still that and is positioned at C-6 position, with
Unlike elaeochytrin B, the benzoyl in noval chemical compound is mono-substituted.Meanwhile, H-11/C-7, H-11/C-8,
It is double bond between dependency explanation C-7 and C-8 between H-6/C-7 and H-6/C-8.Further HMBC spectrum resolves and finds,
Coherent signal between H-13/C-12, H-13/C-4, H-14/C-4 illustrates that another double bond additional is in C-4 and C-
12.In NOESY spectrum, H3The dependency of-15 and H-6 shows H3-15 and H-6 is beta comfiguration, then benzoyl is in α position
's.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and NOESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this change
Compound is as follows, and spatial configuration is determined by ECD test further, and theoretical value is basically identical with experiment value.
This compound chemical formula and carbon atoms numbered are as follows:
Embodiment 2: pharmacological action
The present embodiment uses scribing peel off rat gingiva and feed and prepare rats with experimental periodontitis model with white sugar, and observation medicine changes
Kind animal red swelling of gingiva, ulcer, the effect of the periodontitis of the aspects such as atrophy.
1, materials and methods
1.1 animal
Select tooth body denture complete, the bad and 5 week old SD rats of periodontal disease without dental caries, male and female half and half, body weight 200 ± 20g, by
Animal Experimental Study center, Hubei Province provides.
1.2 reagent and sample
Cefoperazone is purchased from Nat'l Pharmaceutical & Biological Products Control Institute.Compound (I) is made by oneself, and preparation method is shown in embodiment 1.In vain
Saccharum Sinensis Roxb., is made into 10% sucrose solution as drinking water, and conventional feed is soaked into soft feedstuff with this sucrose solution when feeding.Safe (the compound recipe chlorhexidine of mouth
Gargarism), Shenzhen Nanyue Pharmaceuticals Co., Ltd.
1.3 instrument
Ophthalmology and operating equipment are a set of；Syringe；Stereoscope；The full-automatic blood counting instrument of animal, the special health limited public affairs of science and technology
Department.
Prepared by 1.4 rat packets and model
Rat is randomly divided into 6 groups, often 13 rats of group (wherein putting to death after 2 weeks in modeling for 1, take pathological material), point cage
Raise in the facility using licence achieved with barrier environment, respectively Normal group, model control group, positive controls
(mouth Thailand group, 10mg kg-1) and cefoperazone group (10mg kg-1), compound (I) group (10mg kg-1), cefoperazone with
Compound (I) compositions group [5mg kg-1Cefoperazone+5mg kg-1Compound (I)].With a big tweezers opening, with eye
Section's curved scissors carries out scribing stripping to both sides tooth surrounding gum, then feed with 10% white sand sucrose solution and feed white sand sucrose solution
The soft feedstuff soaked, modeling terminates to use instead normal diet, observes animal state every day.
After modeling success, twice daily according to dropleting medicine-feeding in above-mentioned dosage oral cavity, after medication, prohibit diet 4h.Successive administration
3 days.
1.5 gingival hemorrhage indexes (sulus bleeding index, SBI) determination experiment
Periodontal pocket or gingival sulcus 10s selecting tooth is gently visited: the most hemorrhage, free gingival margin NIP is 0 with probe；Free gingival margin without
Redness, it is 1 that spy is examined hemorrhage；The rubescent edema of free gingival margin, it is 2 that spy is examined hemorrhage；Hematostaxis, gingiva is the redst and the most swollen, and ulcer is
3。
1.6 plaque indexs (plaque index, PLI) determination experiment
Dipping in disclosing agent (2% basic fuchsin) with little cotton grain to be applied to select on tooth after 30s, tap water rinses 10s, observes
Mauve area and depth situation on facing, Jin Yinyuan district is 0 without bacterial plaque, and Jin Yinyuan district facing has thin bacterial plaque to be 1, gum edge or
Proximal surface has bacterial plaque to be 2, and gingival sulcus and/or gum edge and vicinal face have a large amount of bacterial plaque to be 3.
The degree of depth (probing depth, PD) determination experiment is examined in 1.7 spies
Visit with the mandrin of scale (scale unit 3mm) with self-control and select tooth periodontal pocket, cheek during the choosing of every tooth is near, cheek side,
In remote, 3 points of cheek are measured, and take average.
1.8 tooth mobilityes (Tooth mobility, TM) determination experiment
Not loosening is 0, and the slight i.e. buccally that loosens is 1 to loosening, and moderate loosens and i.e. loosens to middle-distant direction is 2, severe pine
Moving the most vertical is 3 to loosening.
1.9 frontal resorption values (alveolar bone loss, ABL) determination experiment
At rat after death, taking off head, boiling water boiling, fleshing deposits bone, measures, under anatomical lens from enamelo-cemental junction to alveolar bone
The length on ridge top, during the choosing of every tooth is near, tongue, tongue side, remote middle 3 points of tongue are measured, and take average.
1.10 statistical method
Experimental data mean ± standard deviation (x ± s) represents, application SPSS18.0 version statistical software carries out single factor test variance
Analyze and t checks, statistically significant for difference with P ＜ 0.05.
2, experimental result
2.1 on Periodontitis Model rat gingival hemorrhage index (SBI), plaque index (PLI), visit and examine the impact of the degree of depth (PD)
With Normal group ratio, model control group rat gingival hemorrhage index SBI, plaque index PLI, visit that to examine degree of depth PD obvious
Increase (P ＜ 0.01)；With model control group ratio, cefoperazone refers to compound (I) compositions group and mouth Thailand group rat gingival hemorrhage
Number SBI, plaque index PLI, spy are examined degree of depth PD and are substantially reduced (P ＜ 0.01)；With model control group ratio, cefoperazone group, chemical combination
Thing (I) group rat gingival hemorrhage index SBI, plaque index PLI, spy are examined degree of depth PD and are reduced (P ＜ 0.05).
Experimental result is shown in Table 1.
2.2 on Periodontitis Model rat alveolar bone absorption value (ABL) and the impact of tooth mobility (TM)
Comparing with Normal group, the frontal resorption value of model control group rat and tooth mobility substantially increase (P ＜
0.01).Compare with model control group, cefoperazone and compound (I) compositions group and mouth Thailand group frontal resorption value and tooth
Movable degree is obviously reduced (P ＜ 0.01)；Compare with model control group, cefoperazone group, compound (I) group frontal resorption value and
Tooth mobility reduces (P ＜ 0.05).The results are shown in Table 1.
Table 1 is on the improvement of Periodontitis Model rat clinical indices and frontal resorption value, the impact of tooth mobility
Periodontitis is prepared in the most conventional local excitation or systemic factor+local excitation effect jointly.Main local excitation
Because of have high-carbonhydrate diet, ligature, the method such as stimulation, Oral inoculation specific bacterium of performing the operation, oneself factor hormone to be applied presses down with immunity
Preparation.Applying hormone or IM modeling or cycle long, model is unstable, or differs with clinical pathology change
Cause, or inconvenient operation, easily make animal dead or individual variation is big waits deficiency, affect the O&A of curative effect of medication.
This experiment uses to be partially stripped and adds high sugar feed and the method for height sugar drinking-water nursing, makes laboratory animal oral cavity significantly
Occur in that dysbacteriosis and similar mankind's periodontitis pathological change.Gingiva is partially stripped provides fixation point into high sugar feed, can make
Anaerobe fast breeding, high sugar drinking-water provides good environment for anaerobe growth, and high sugar feed carries for anaerobe growth further
For stable nutrition and environment.It is convenient and easy that the method prepares model, it is simple to universal, experimental period is short, and two to three weeks got final product shape
Becoming typical case's periodontitis, and visible periodontal pocket is formed, model stability, individual variation is little.
Periodontal probing is the most important inspection method of periodontal disease, examines the degree of depth including spy and the contents such as bleeding positive rate are examined in spy.
It is the most important pathological change of periodontitis that the inflammation of gingiva and hemorrhage and periodontal pocket are formed.The degree of depth is examined in spy can reflect deep periodontal pocket
The change of degree, bag deep person inflammation is heavier；It is that display gingiva has the more objective index of NIP, spy to examine the most hemorrhage that spy is examined the most hemorrhage
Tooth position prompting periodontal tissue be in relatively health status, bleeding positive position is then pointed out needs continual cure.
Result shows, when cefoperazone, compound (I) independent role, periodontitis is had therapeutical effect；Cefoperazone and
During compound (I) synergy, therapeutic effect improves further, can develop into the medicine for the treatment of periodontitis.
The effect of above-described embodiment indicates that the essentiality content of the present invention, but does not limit the protection of the present invention with this
Scope.It will be understood by those within the art that, technical scheme can be modified or be equal to and replace
Change, without deviating from essence and the protection domain of technical solution of the present invention.
Claims (5)
1. the pharmaceutical composition of a cefoperazone, it is characterised in that: include cefoperazone, there is the compound of following structural formula
(I) and pharmaceutically acceptable carrier, is prepared as the dosage form needed；
The pharmaceutical composition of cefoperazone the most according to claim 1, it is characterised in that: pharmaceutically acceptable carrier
Including diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier
Or lubricant.
The pharmaceutical composition of cefoperazone the most according to claim 1, it is characterised in that: described dosage form includes tablet, glue
Wafer, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection,
Suppository, spray, drop or patch.
The pharmaceutical composition of cefoperazone the most according to claim 1, it is characterised in that described compound (I) is by following
Step is prepared: (a) by Fructus Sinopodophylli pulverize, with 80～90% alcohol heat reflux extraction, united extraction liquid, be concentrated into without alcohol
Taste, successively with petroleum ether, ethyl acetate and water saturated n-butanol extraction, respectively obtains petroleum ether extract, ethyl acetate extraction
Take thing and n-butyl alcohol extract；B in () step (a), n-butyl alcohol takes thing macroporous resin remove impurity, first with 6 posts of 30% ethanol elution
Volume, then with 12 column volumes of 85% ethanol elution, collect 85% eluent, concentrating under reduced pressure obtains 85% ethanol elution concentrate；
In (c) step (b) 85% ethanol elution concentrate with purification on normal-phase silica gel separate, successively with volume ratio be 100:1,50:1,25:1 and
The methylene chloride-methanol gradient elution of 12:1 obtains 4 components；D in () step (c), component 4 separates further by purification on normal-phase silica gel,
3 components are obtained successively with the methylene chloride-methanol gradient elution that volume ratio is 20:1,12:1 and 2:1；Group in (e) step (d)
Points 2 separate with the reverse phase silica gel of octadecylsilane bonding, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 88%,
Collecting 13～16 column volume eluents, eluent is concentrated under reduced pressure to give compound (I).
The pharmaceutical composition of cefoperazone the most according to claim 4, it is characterised in that described macroporous resin is D101 type
Macroporous adsorbent resin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610564494.5A CN106187777A (en) | 2016-07-14 | 2016-07-14 | A kind of pharmaceutical composition of cefoperazone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610564494.5A CN106187777A (en) | 2016-07-14 | 2016-07-14 | A kind of pharmaceutical composition of cefoperazone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106187777A true CN106187777A (en) | 2016-12-07 |
Family
ID=57493034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610564494.5A Pending CN106187777A (en) | 2016-07-14 | 2016-07-14 | A kind of pharmaceutical composition of cefoperazone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106187777A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879627A (en) * | 2006-05-17 | 2006-12-20 | 济南帅华医药科技有限公司 | A sustained release injection containing cephalosporin and application thereof |
| CN104961791A (en) * | 2015-06-05 | 2015-10-07 | 中国科学院西北高原生物研究所 | Novel triterpene compound in potentilla anserina, and preparation method and application thereof |
| CN105017276A (en) * | 2015-08-19 | 2015-11-04 | 庄立 | Five-membered epoxy structure compound for treating pancreatic cancer |
| CN105061413A (en) * | 2015-09-06 | 2015-11-18 | 叶澄 | New limonin compound and pharmaceutical composition containing same, and preparation method and application thereof |
| CN105111196A (en) * | 2015-09-06 | 2015-12-02 | 叶澄 | Highly-esterified limonin compound and medical application thereof |
| CN106046017A (en) * | 2016-06-07 | 2016-10-26 | 黄芳 | Medicine composition containing huperzine-A and medical application of medicine composition |
-
2016
- 2016-07-14 CN CN201610564494.5A patent/CN106187777A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879627A (en) * | 2006-05-17 | 2006-12-20 | 济南帅华医药科技有限公司 | A sustained release injection containing cephalosporin and application thereof |
| CN104961791A (en) * | 2015-06-05 | 2015-10-07 | 中国科学院西北高原生物研究所 | Novel triterpene compound in potentilla anserina, and preparation method and application thereof |
| CN105017276A (en) * | 2015-08-19 | 2015-11-04 | 庄立 | Five-membered epoxy structure compound for treating pancreatic cancer |
| CN105061413A (en) * | 2015-09-06 | 2015-11-18 | 叶澄 | New limonin compound and pharmaceutical composition containing same, and preparation method and application thereof |
| CN105111196A (en) * | 2015-09-06 | 2015-12-02 | 叶澄 | Highly-esterified limonin compound and medical application thereof |
| CN106046017A (en) * | 2016-06-07 | 2016-10-26 | 黄芳 | Medicine composition containing huperzine-A and medical application of medicine composition |
Non-Patent Citations (1)
| Title |
|---|
| FERDINAND BOHLMANN ET AL.: "A daucanolide and further farnesene derivatives form ageratum F astigiatum", 《PHYTOCHEMISTRY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106046017A (en) | Medicine composition containing huperzine-A and medical application of medicine composition | |
| CN102018766A (en) | Plant extractive, extraction method and application thereof as well as composite comprising same | |
| CN1762967B (en) | Enoxolone derivative, preparation method and uses | |
| CN101147724A (en) | Medicine or sanitary product containing licorice flavone extraction for oral cavity | |
| CN108324739B (en) | Pharmaceutical composition and application thereof, oral cleaning and nursing product, oral health product and medicine | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105726792A (en) | Traditional Chinese medicine composition with effects of resisting periodontitis and protecting periodontium and preparation method and application thereof | |
| CN103784856B (en) | A kind of Chinese medicine composition treating periodontitis and method for making thereof and application | |
| CN106146315A (en) | A kind of medicinal compound and preparation method thereof | |
| CN106187777A (en) | A kind of pharmaceutical composition of cefoperazone | |
| CN106265623A (en) | Compound, cefoperazone pharmaceutical composition preparation treatment periodontitis medicine in application | |
| CN101028348A (en) | Chinese medicinal capsule, its production and quality controlling method | |
| CN101837044A (en) | Extraction method of wild herba Sophora alopecuroide and oral medicinal composition | |
| CN115400194A (en) | Traditional Chinese medicine composition for treating childhood epidemic and application thereof | |
| CN112137940B (en) | Compound sugarcane leaf toothpaste and preparation method thereof | |
| CN102836277B (en) | Medicine composition for treating periodontal diseases as well as preparation method and application thereof | |
| CN105101969B (en) | Antivirotic composition comprising boric acid, citric acid and zinc | |
| CN103263508B (en) | Traditional Chinese medicine composition for treating swine toxoplasmosis as well as preparation and application thereof | |
| CN106177082A (en) | A kind of preparation method and application of compound phellodendron bark liquid varnish | |
| CN105753830A (en) | Estazolam medicine composition and application thereof in biological medicine | |
| KR20110023531A (en) | Cosmetic composition for improving bust drooping and elasticity | |
| CN100453073C (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN103099820B (en) | Streptococcus mutans infection and cariogenic animal model establishing method | |
| CN107362184A (en) | The purposes of penthorum chinense pursh and its extract in the oral cavity medicine thing for the treatment of or/and prevention of gingivitis is prepared | |
| CN107793403A (en) | A kind of noval chemical compound with epoxy construction and preparation method thereof and medical usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161207 |